In the last few decades, in the field of Drug Discovery, Immunotherapy has gained more and more importance for the treatment of various diseases and in particular for certain types of cancer. Based on inducing, enhancing or suppressing an immune response, this therapeutic manipulation has led to promising clinical results.
Major regulators of Immune activation, Immune checkpoints play a key role in maintaining immune homoeostasis and preventing autoimmunity. However in some cancers, these checkpoints can be used to avoid any activation of the immune response against cancer cells. Immunotherapies based on targeting immune checkpoint pathways in Drug Discovery, have already led to the development of promising molecules (Nivolumab, Pembrolizumab…) tested in clinical trials and approved, which are giving new hope for cancer treatments.
Human Peripheral Blood Mononuclear Cells (hPBMCs) are essential for designing cellular models to be used in cell therapy and drug discovery research programs [1-7, 12]. Being able to access reliable and ethical sources of well-characterized hPBMCs is now becoming fundamental for running physiologically relevant cell-based assays. A good opportunity to discuss the expanding applications for hPBMCs in drug development.
Analyte quantification (in pg/ml or ng/ml) such as IL-6, TNFalpha and numerous other proteins is conveniently performed with immunoassays called ELISA kits. At tebu-bio, we not only provide more than 10 000 ELISA kits but we also support researchers through our techserv team who are on-hand to suggest the best kits and to answer any questions.
Being part of that team, I have noticed a number of often asked questions that can be resumed in one : What is the best method for data analysis?